Chris Ryan

Treatment with talazoparib and enzalutamide appears to yield a statistically significant and clinically meaningful radiographic progression-free survival benefit compared with placebo/enzalutamide in frontline metastatic castration-resistant prostate cancer regardless of homologous recombination repair status.

A combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline yields a statistically significant survival benefit compared with nab-paclitaxel and gemcitabine in a population diagnosed with metastatic pancreatic ductal adenocarcinoma.

Findings from the phase 1b/2 KRYSTAL-1 trial showed encouraging responses with adagrasib in patients with advanced KRAS G12C-mutant colorectal cancer.

The final readout of the phase 2 TITAN-RCC trial highlighted an improvement in responses following an individualized regimen of nivolumab and ipilimumab boost after single-agent nivolumab in patients with advanced renal cell carcinoma.

The nonsteroidal selective estrogen receptor modulator lasofoxifene resulted in better clinical benefit vs fulvestrant in patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutant metastatic breast cancer.

Results from the phase 2 SYNERGY trial suggest little or no benefit of adding oleclumab to durvalumab and chemotherapy for advanced frontline triple-negative breast cancer.

Results from the phase 3 RATIONALE-303 trial presented at 2022 WCLC showed an overall survival benefit when patients with non–small cell lung cancer were treated with second- or third-line tislelizumab compared with docetaxel.

TROPION-Lung02 trial provides evidence of datopotamab deruxtecan and pembrolizumab efficacy in patients with advanced/metastatic non–small cell lung cancer and no actionable genomic alterations.

The novel KRAS G12C inhibitor GDC-6036 induced a high response rate in patients with previously treated KRAS G12C mutation–positive non–small cell lung cancer.

Treatment strategies might be better tailored through the use of next-generation sequencing to detect NRG1 fusions.

Follow-up results of the phase 3 ASPEN trial comparing zanubrutinib with ibrutinib in patients with Waldenström macroglobulinemia were presented at 2022 ASCO.

Results from the phase 2 CRESTONE trial showed positive overall response rates in patients with solid tumors harboring NRG1 fusions treated with seribantumab monotherapy.

Results of the CHOICE-01 trial demonstrate the utility of toripalimab added to chemotherapy in advanced frontline non–small cell lung cancer at 2022 ASCO.

Superior post-scan disease upstaging in patients with recurrent prostate cancer was observed with 18F-rhPSMA-7.3 compared with conventional baseline imaging.

Treatment with several CAR T-cell products resulted in notable responses without an increase in cytokine release syndrome or neurotoxicity in large B-cell lymphoma with central nervous system involvement.

Novel BO-112 when combined with pembrolizumab may offer a new treatment option for patients with advanced melanoma and PD-1 inhibitor therapy resistance.

Ibrutinib plus venetoclax given at a fixed duration yielded favorable progression-free survival in patients with previously untreated, high-risk chronic lymphocytic leukemia and small lymphocytic lymphoma.

Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.

Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.

At a recent conference, Robert Dreicer, MD, MS, MACP, FASCO, offered his advice regarding the use of androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer.

Adding pembrolizumab to chemotherapy does not improve outcomes over chemotherapy alone in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to updated results of the KEYNOTE-062 trial.

Patients receiving hematopoietic stem cell transplantation appeared to have improved outcomes and a decreased incidence of acute graft-versus-host disease after being treated with itolizumab.

Patients with triple-class relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel saw a greater survival benefit over physician's choice of treatment.

Second-line treatment of lisocabtagene maraleucel demonstrated improved quality of life in patients with large B-cell lymphoma.

Ciltacabtagene autoleucel as a single infusion led to early, durable responses, and demonstrated positive minimal residual disease negativity for patients with multiple myeloma who had early clinical relapse.

Adding isatuximab to lenalidomide, bortezomib, and dexamethasone demonstrated a superior minimal residual disease rate in patients with transplant-eligible newly diagnosed multiple myeloma.

Tucatinib plus palbociclib and letrozole prolonged central nervous system progression-free survival for patients with hormone receptor–positive, HER2-positive breast cancer.

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.